Literature DB >> 33546407

The Spectrum of Antimicrobial Activity of Cyadox against Pathogens Collected from Pigs, Chicken, and Fish in China.

Muhammad Kashif Maan1, Zhifei Weng1, Menghong Dai1, Zhenli Liu1, Haihong Hao1, Guyue Cheng1, Yulian Wang1, Xu Wang1, Lingli Huang1.   

Abstract

Cyadox has potential use as an antimicrobial agent in animals. However, its pharmacodynamic properties have not been systematically studied yet. In this study, the in vitro antibacterial activities of cyadox were assayed, and the antibacterial efficacy of cyadox against facultative anaerobes was also determined under anaerobic conditions. It was shown that Clostridium perfringens and Pasteurella multocida (MIC = 0.25 and 1 μg/mL) from pigs, Campylobacter jejuni and Pasteurella multocida from poultry, E. coli, Streptococcus spp., and Flavobacterium columnare from fish were highly susceptible to cyadox (MIC= 1 and 8 μg/mL). However, F. columnare has no killing effect for drug tolerance. Under in vitro anaerobic conditions, the antibacterial activity of cyadox against most facultative anaerobes was considerably enhanced Under anaerobic conditions for the facultative anaerobes, susceptible bacteria were P. multocida, Aeromonas spp. (including A. hydrophila, A. veronii, A. jandaei, A. caviae, and A. sobria, excluding A. punctata), E. coli, Salmonella spp. (including S. choleraesui, S. typhimurium, and S. pullorum), Proteus mirabilis, Vibrio fluvialis, Yersinia ruckeri, Erysipelothrix, Acinetobacter baumannii, and Streptococcus agalactiae (MICs were 0.25~8 μg/mL, MBCs were 1-64 μg/mL). Intermediate bacteria were Enterococcus spp. (including E. faecalis and E. faecium), Yersinia enterocolitica, and Streptococcus spp. (MICs mainly were 8~32 μg/mL, MBCs were 16~128 μg/mL). This study firstly showed that cyadox had strong antibacterial activity and had the potential to be used as a single drug in the treatment of bacterial infectious diseases.

Entities:  

Keywords:  antimicrobial activity; clinical breakpoints; cyadox; pathogenic bacteria

Year:  2021        PMID: 33546407      PMCID: PMC7913539          DOI: 10.3390/antibiotics10020153

Source DB:  PubMed          Journal:  Antibiotics (Basel)        ISSN: 2079-6382


  17 in total

1.  Pharmacokinetic-pharmacodynamic modeling of cyadox against Escherichia coli in swine.

Authors:  Lingli Huang; Muhammad Kashif Maan; Dongting Xu; Muhammad Abu Bakr Shabbir; Menghong Dai; Zonghui Yuan
Journal:  Microb Pathog       Date:  2019-07-31       Impact factor: 3.738

2.  Olaquindox and cyadox stimulate growth and decrease intestinal mucosal immunity of piglets orally inoculated with Escherichia coli.

Authors:  M X Ding; Z H Yuan; Y L Wang; H L Zhu; S X Fan
Journal:  J Anim Physiol Anim Nutr (Berl)       Date:  2006-06       Impact factor: 2.130

3.  Metabolism of cyadox by the intestinal mucosa microsomes and gut flora of swine, and identification of metabolites by high-performance liquid chromatography combined with ion trap/time-of-flight mass spectrometry.

Authors:  Ning Xu; Lingli Huang; Zhenli Liu; Yuanhu Pan; Xu Wang; Yanfei Tao; Dongmei Chen; Yulian Wang; Dapeng Peng; Zong hui Yuan
Journal:  Rapid Commun Mass Spectrom       Date:  2011-08-30       Impact factor: 2.419

4.  The mechanism of enzymatic and non-enzymatic N-oxide reductive metabolism of cyadox in pig liver.

Authors:  Ming Zheng; Jun Jiang; Junping Wang; Xianqing Tang; Man Ouyang; Yiqun Deng
Journal:  Xenobiotica       Date:  2011-07-11       Impact factor: 1.908

5.  Acute and subchronic toxicological evaluation of Mequindox in Wistar rats.

Authors:  Awais Ihsan; Xu Wang; Xian-ju Huang; Yu Liu; Qin Liu; Wen Zhou; Zong-hui Yuan
Journal:  Regul Toxicol Pharmacol       Date:  2010-04-03       Impact factor: 3.271

6.  Experimental evaluation of cyadox phototoxicity to Balb/c mouse skin.

Authors:  Qinghua He; Guijie Fang; Yulian Wang; Zhichao Wei; Daju Wang; Shiqi Zhou; Shengxian Fan; Zanghui Yuan
Journal:  Photodermatol Photoimmunol Photomed       Date:  2006-04       Impact factor: 3.135

7.  Mode of action of quindoxin and substituted quinoxaline-di-N-oxides on Escherichia coli.

Authors:  W Suter; A Rosselet; F Knüsel
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

8.  Pharmacokinetic and pharmacodynamic modeling of cyadox against Clostridium perfringens in swine.

Authors:  Lei Yan; Shuyu Xie; Dongmei Chen; Yuanhu Pan; Yanfei Tao; Wei Qu; ZhenLi Liu; Zonghui Yuan; Lingli Huang
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

Review 9.  Rapid culture-based diagnosis of pulmonary tuberculosis in developed and developing countries.

Authors:  Shady Asmar; Michel Drancourt
Journal:  Front Microbiol       Date:  2015-11-03       Impact factor: 5.640

10.  In vitro antimicrobial activities of animal-used quinoxaline 1,4-di-N-oxides against mycobacteria, mycoplasma and fungi.

Authors:  Yan Zhao; Guyue Cheng; Haihong Hao; Yuanhu Pan; Zhenli Liu; Menghong Dai; Zonghui Yuan
Journal:  BMC Vet Res       Date:  2016-09-06       Impact factor: 2.741

View more
  2 in total

1.  Synthesis and Characterization of Novel 2-Acyl-3-trifluoromethylquinoxaline 1,4-Dioxides as Potential Antimicrobial Agents.

Authors:  Galina I Buravchenko; Dmitry A Maslov; Md Shah Alam; Natalia E Grammatikova; Svetlana G Frolova; Aleksey A Vatlin; Xirong Tian; Ivan V Ivanov; Olga B Bekker; Maxim A Kryakvin; Olga A Dontsova; Valery N Danilenko; Tianyu Zhang; Andrey E Shchekotikhin
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-27

2.  Optimization of Veterinary Antimicrobial Treatment in Companion and Food Animals.

Authors:  Nikola Puvača
Journal:  Antibiotics (Basel)       Date:  2022-08-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.